<SEC-DOCUMENT>0001654954-19-005572.txt : 20190509
<SEC-HEADER>0001654954-19-005572.hdr.sgml : 20190509
<ACCEPTANCE-DATETIME>20190509171133
ACCESSION NUMBER:		0001654954-19-005572
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190507
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190509
DATE AS OF CHANGE:		20190509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		19811720

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNITED STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<a name="_DV_M1"><!--anchor--></a>SECURITIES AND
EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Washington, D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 8-K</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CURRENT REPORT</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (date of earliest event reported): May 7, 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of Registrant as specified in its charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">
&#xA0;</font><font style="font-style: italic">Colorado</font></font></div>
</td>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">
&#xA0;</font><font style="font-style: italic">01-11889</font></font></div>
</td>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">
&#xA0;</font><font style="font-style: italic">84-0916344</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">
&#xA0;</font>(State or other jurisdiction<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>of
incorporation)</font></div>
</td>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">
&#xA0;</font>(Commission File No.)</font></div>
</td>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">
&#xA0;</font>(IRS Employer<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>Identification
No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Boulevard, Suite 802</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-style: italic; font-family: Times New Roman; font-size: 13px">
Vienna, Virginia 22182</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Address
of principal executive offices, including Zip Code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Registrant&#x2019;s
telephone number, including area
code:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; (703)
506-9460</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-style: italic; font-family: Times New Roman; font-size: 13px">
N/A</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Former
name or former address if changed since last report)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA8;</font>
<font style="font-family: Times New Roman; font-size: 13px">Written
communications pursuant to Rule 425 under the Securities Act (17CFR
230.425)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA8;</font>
<font style="font-family: Times New Roman; font-size: 13px">Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA8;</font>
<font style="font-family: Times New Roman; font-size: 13px">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA8;</font>
<font style="font-family: Times New Roman; font-size: 13px">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-14c))</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;203.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;204.12b-2 of this chapter.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company &#x2610;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#x2610;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font>&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 96px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
3.02.&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Unregistered
Sales of Equity Securities.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has received security purchase agreements for the purchase
of 30,612 restricted shares of the Company&#x2019;s common stock at
the closing price on May 6, 2019 of $6.86 in the principal amount
of approximately $210,000 from five officers and directors of the
Company. As of May 9, 2019, the Company had 33,702,852 outstanding
shares of common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company relied upon the exemption provided by Section 4(a)(2) of
the Securities Act of 1933 in connection with sale of the shares
described above. The persons who acquired these shares were
sophisticated investors and were provided full information
regarding the Company&#x2019;s business and operations. There was no
general solicitation in connection with the offer or sale of these
shares. The persons who acquired these shares acquired them for
their own accounts. The certificates representing the shares will
bear a restricted legend providing that they cannot be sold except
pursuant to an effective registration statement or an exemption
from registration. No commission was paid to any person in
connection with the sale of these shares.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 96px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
8.01&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Other
Events.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On May
8, 2019, the Company issued a press release, filed as Exhibit 99,
providing an update on the status of the Phase 3 clinical
study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 96px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
9.01.</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Financial
Statements and Exhibits.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 144px"><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Exhibit</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Description</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 144px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;<a href="cvm_ex991.htm">99</a></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Press Release dated
May 8, 2019</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">CEL-SCI
CORPORATION</font>&#xA0;<br></font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Date: May 9,
2019</font></font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/&#xA0;
<font style="font-family: Times New Roman; font-size: 13px">Patricia
Prichep<br></font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 11px"><font style="font-size: 13px">Patricia Prichep</font></font><br></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-size: 13px">Senior
Vice President of Operations</font></font><br></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<br>
&#xA0;
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>cvm_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
Exhibit 99</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_ex991000.jpg"></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, May 8, 2019 --</font> The following letter was sent by
CEL-SCI Corporation (NYSE American: CVM) to its
shareholders:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dear
CEL-SCI Shareholders:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
first 4 months of this year have already been very positive for us.
Our Phase 3 head and neck cancer study is continuing and we are
moving forward with our Rheumatoid Arthritis product development.
Since January 1, we have received about $9.6 million from the
conversion of warrants to finance our ongoing
projects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
believe the following developments with regard to the Multikine*
Phase 3 trial have contributed to additional investments in our
Company:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Length of Phase 3 study could be a
sign of Multikine&#x2019;s efficacy</font>:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We have
not yet hit the primary endpoint of our 928 patient Phase 3 study
with our investigational cancer immunotherapy drug Multikine. That
endpoint will be reached when 298 events (deaths) have occurred and
are recorded in the two main comparator arms of the study. Since
the scientific literature does not suggest an improvement in the
survival rates for oral head and neck cancer patients receiving
standard of care only, we believe a delay in reaching these 298
events could be a good sign for the potential effectiveness of
Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">The IDMC recommended to continue the
Phase 3 cancer study after their review of our
data</font>:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">At the
end of March 2019, we had an official review of the Phase 3 study
by the IDMC (Independent Data Monitoring Committee). The IDMC
recommended to &#x201C;continue the trial until the appropriate
number of events has occurred&#x201D;. The IDMC reviews all the
study results at the time of each IDMC meeting. Had the study
results indicated that meeting the primary survival endpoint of the
study would no longer be possible, the study could have been deemed
futile. The IDMC recommended to continue the study. In our Phase 3
trial the primary endpoint is met by reaching a 10% improvement in
the overall survival of the group of patients receiving the
Multikine treatment regimen plus the Standard of Care versus the
overall survival of the group of patients receiving the Standard of
Care only. Futility has been on the minds of investors a lot more
recently, because finding futility in the case of a Phase 3
Alzheimer study by Biogen in March 2019 resulted in a loss to
shareholders of close to $30 billion.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Our
goal is to use Multikine immunotherapy to increase the success rate
of the first &#x201C;intent to cure&#x201D; cancer treatment regimen
by adding the tumor cell killing ability of the still healthy
immune system to the known anti-tumor effects of surgery, radiation
and chemotherapy. In short, our goal is to use the immune system,
while it is still strong, to make the first cancer treatment more
successful so that patients do not progress and become terminal
cancer patients. This approach is unique to CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I have
been traveling extensively since the beginning of the year to
communicate to the investment community our new way of treating
cancer, administrating cancer immunotherapy right after diagnosis
and BEFORE surgery. When we started the Phase 3 study over eight
years ago, hardly anyone believed that cancer immunotherapy would
ever be successful. Now just about everyone I meet with sees cancer
immunotherapy as the future of cancer treatment. Only a few years
ago investors told me that it was not necessary to treat before
surgery, radiation and chemotherapy because the immune system
recovers. Now investors appear to agree that activating the immune
system to fight cancer before surgery, radiation and chemotherapy
have severely compromised the immune system, should be the most
effective way of treating cancer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">What
few of these investors understood is that existing cancer drugs,
even the newly approved immunotherapy drugs you read about in the
news almost every week, cannot be given right after diagnosis and
before the first &#x201C;intent to cure&#x201D; treatment of surgery.
Delay of surgery is not allowed and that leaves only three weeks
for treatment between diagnosis and surgery. Multikine fits into
this three week treatment schedule and that makes Multikine
immunotherapy unique. The other cancer immunotherapies require
months of treatments. In addition, given the horrible toxicities
from radiochemotherapy, which often follows surgery in head and
neck cancer and also other cancers, any drug added must not add
toxicity to the already toxic treatment. Multikine, as we learned
from prior studies, satisfies this requirement as
well.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We are
benefiting from renewed interest in CEL-SCI&#x2019;s Multikine
cancer immunotherapy by meeting with new investors weekly. What is
striking is that hardly any of them have ever heard of CEL-SCI,
even though we have been running the largest study ever in head and
neck cancer. We think that the absence of new clinical data for
over 8 years (we are blinded to the Phase 3 results and therefore
could not announce clinical data) is probably the reason for
CEL-SCI being virtually unknown. But, while that presented a
problem in the past, it now represents a fantastic opportunity. New
investors are very interested for two reasons: 1) during our Phase
3 study cancer immunotherapy has become accepted as a new treatment
modality for cancer; and 2) investors prefer investing near the end
of this long trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">It has
taken decades to get to this point in time, but we are finally near
the end, and we feel good about it. Each of the last few years I
have purchased more CEL-SCI stock. And I did so again this week
when I purchased $100,000 worth of restricted CEL-SCI stock at
$6.86 directly from the Company at the full market price. Several
others from our senior management team and one member of the Board
of Directors have joined me and purchased another $110,000 worth of
CEL-SCI stock on the same terms.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">One
last point: We have our Annual Shareholder Meeting on May 20, 2019.
Please participate by voting your shares. If you are having
problems voting or have not received a proxy from your broker,
please call Advantage Proxy at 1-877-870-8565 and talk to
them.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">WE
BELIEVE! We believed when there was little data supporting our
belief. We believe now even more than before. Thank you very much
for your support.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sincerely,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
shareholder letter contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI&#x2019;s filings with
the Securities and Exchange Commission, including but not limited
to its report on Form 10-K for the year ended September 30, 2018.
The Company undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cvm_ex991000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_ex991000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  @&!@<&
M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q
M-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #'
M M@# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BDS[T9]Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>D75_;7UU;RP1%@L3X4X]16I';130VDDB!GB 9"?X3MQ_(FJ?BG_ )%;4O\
MKW;^5 '!^&=1U;6=<BL[C5KQ8BK,VU^3@=*].@A\B%8_,DDQ_%(V6/U->5>
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M-J-U:&"*57\J-B% !&<#')^IK>\0VNJZC8SV-E%:B*:/:TLLI!&>H"A3^>:
M.!\!?\C5%_UR?^5>M5YSI/@[Q#H^HQWMO)8&1 1AW8@@_A70W \830LD8TJ%
MB,;U9R1],C% &C;ZJ;K7KRQCVF*UB0NW?>V>/RQ7FGC?_D;+SZ)_Z"*[7PUH
MFIZ);ZA)/Y%Q>7#*P_>G#8SU./?TK$U?P;KNKZI-?2&QC:3'RK*Q  &!_#[4
M :T^C)JG@[362 /=PQ1/$PQGC&1^6:Z#4=133;>-W&YY)4BC3."S,<?XG\*Q
M+&V\66&GQ6B+I3B)0BL[OG Z=!5)?#WB*\U^SOM5NK:2*"4.$C8X4#G@8]<=
M: .GUK45TK29[L\LBX1?[S'@#\ZP-&L_$FF:>(4M-/=W8R2/),VYF;J3QUI?
M$&D^(-7O(#$;)+6WE$D<;2,=Y!X+?+^GO726;7;6^;V*&.;/2*0NN/J0* /'
M-:TZ[T?5F29$BD)\V/RF)503D8)]/Z5ZUH6J+J^C6]XI^9EPX]&'!'YUSOBC
MP[J_B"ZB9([*)(-RJQF8LX.,9^7CIT]ZD\+Z'KN@2M%*UI+9R,"ZB5LH?4?+
M_G% &S87T.L/J5E<QQ/]GN&B:,C(*=B0:YGQ#X#@$$EWI1,;*"S6Y.0?]T]J
ML#PUK4&NWVK6-W##)),Q6)P2LB=?FQTK0NI/%-W;/;)8V5LSC:T_V@M@=R!B
M@#GOAM<2_;+VWR?),8DQV#9Q_+^54?B'_P C(N/^?=/YM7;Z%X?7P]ILB6VV
M>[<99W.T,>P[X%<YKGA/7M<U)KR3[#%\H1465C@#WV\]: +EKH\>K_#RWB$2
MM<+"7A..=P)( /OT_&NDU/4ETC2'NG7<R* D><%V/ 7\ZPM+L?%6E:;'91#2
MY$CSL9W?(!.>PJI<>'O$FJ:I:SZG<VC6\4RN8HW("@'G QR?J: .X4Y4$C&1
M2T#I10 4444 %8VM7KVMQ9QBZDMXY2^]HX@[' &.,&MFJ%_:7,UQ;SVLT<<D
M.X?O$+ A@/0CTH 8MVMGI1O)IYKE -VXQA6()_N@#^51_P!LG[2UNMA=&8()
M%3"C<O/.<X'3H>:EEL[JZL)+>ZGA+N00T<9  !!Z$FI19XU-KS?]Z 0[<>C$
MY_6@")M6B^QVMRD<LBW+!8U51NR03S^1I8]3B,=PTR/ ]N-TJ/@D C((QD$&
MJDVGW$%EI=M;OE[>89D*Y &QADC/3G'XU,FE/+'>&\F#RW2"-C&NU549Q@$^
MYH FM]0\Z=89()8)'0N@DQ\RC&>A//(X]ZBCUJUDFMH\N&N$=QD<+MZ@^AZ_
MD:?!97!O([F[GCD:)&2,1IM'.,D\GG@52G\.I*MX$N'C:XE#J0/]6.=P'UW-
M_P!]4 6WU>);>VE6-V:Y&Z./(!(ZY))P.H_.B36K:/34OB)&C:01;5&6#%MN
M,?6B_P!+6Z-N\8A#0 JJRQ[T*G'&/P%']EDV-O;ET!CF24E(PH)#;L #IZ4
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MDFLS,2?7(=<?2@#7HKF?[.\8?]#'IG_@J;_X[1_9WC#_ *&/3/\ P5-_\=H
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M016^FJVQ0S LS,V"2<  8  !]:EUKPYK4WC!M:TU-(FCDL$LWCU .=I61VW
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MC4+?SH7N)[RYN8FP=H\QV90>_&1FMBP%XMA;C4&A:\$8\XP A"^.=N><9]:
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M?$TFNP:]J%G<M$(46-(76->X3S$8KD\G'6F_\(1-'X@NM9@\2:I%<W)42?)
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MT?ER2'6]1;4&OEOQ?'RO,641^7PNS9C;QC;780HT<$:/(TC*H!=L98^IQQ0
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M5L@8H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
